



Updated Monthly

January 8, 2025

Prepared for:



THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding

Published by:



Questions?

Liz Powell, Esq., MPH

lpowell@G2Gconsulting.com

www.G2Gconsulting.com


  @G2Gconsulting





TABLE OF CONTENTS

New Opportunities

Agriculture.....	2
Amyotrophic Lateral Sclerosis	2
Artificial Intelligence & Machine Learning	2
Autism.....	3
Bioengineering.....	3
Biomedical Research.....	4
Cancer	6
Cardiovascular and Pulmonary Health.....	8
Chronic Pain & Pain Management	9
Cognitive and Brain Health.....	9
Communication Disorders.....	10
Diversity and Inclusion.....	11
Endocrine & Metabolic Disease	11
Energy Science	12
Genomics	12
Health IT & Data.....	13
HIV/AIDS	14
Immunology & Infectious Disease	15
Maternal and Pediatric Health	15
Medical Countermeasures.....	15
Mental Health.....	16

GBG Report

Updated Monthly

January 8, 2025

<https://www.g2gconsulting.com/gbg-reporting-service/>

Microgravity Research.....	16
Rare Diseases	17
Small Business Development	17
Social Determinants of Health	17
Substance Use Disorder	18
Therapeutics.....	19
Tuberous Sclerosis Complex	19
Vision Health	19
Women's Health.....	20

Recurring Opportunities

Advanced Research Projects Agency for Health	21
Air Force	22
BARDA	24
DARPA	25
Defense Threat Reduction Agency	25
Department of Energy.....	26
National Science Foundation	26
Navy	27
Office of the Undersecretary of Defense	27
Patient-Centered Research Institute	28

GBG Acronyms	30
---------------------------	-----------



January 16, 2025 – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 12-12:30pm EST (FREE to all) and 12:30-1:00pm (premium service private consultation for G2G and GBG clients). If you’re an affiliate of BioUtah, Bio Nebraska, Focused Ultrasound Foundation, iBIO, Indiana Life Sciences Association, IowaBio, MichBio, NCBiotech, Ohio Life Sciences, South Dakota Biotech, or VaBio – your membership gets you access to the private consultation webinar.

MHSRS 2025 – [The call for abstracts is open!](#) G2G will offer tips for submitting during a [webinar on January 22 at 12pm EST](#). Abstracts are due February 16 for the conference, which is tentatively scheduled for August 4-7.

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AGRICULTURE (1)		
1.	Agriculture and Food Research Initiative Competitive Grants Program Foundational and Applied Science Program (USDA/NIFA) USDA-NIFA-AFRI-011134	The AFRI Foundational and Applied Science Program supports grants in six AFRI priority areas to advance knowledge in both fundamental and applied sciences important to agriculture. The six priority areas are: Plant Health and Production and Plant Products; Animal Health and Production and Animal Products; Food Safety, Nutrition, and Health; Bioenergy, Natural Resources, and Environment; Agriculture Systems and Technology; and Agriculture Economics and Rural Communities. https://www.nifa.usda.gov/grants/funding-opportunities/agriculture-food-research-initiative-foundational-applied-science	Up to \$1.15 million	Deadlines vary according to program area
		AMYOTROPHIC LATERAL SCLEROSIS (4)		
2.	Forecast: FY25 Amyotrophic Lateral Sclerosis Research Program (DoD/CDMRP)	The FY25 ALSRP anticipates four awards that will support development of effective treatments for ALS: Pilot Clinical Trial Award; Clinical Outcomes and Biomarkers Award; Therapeutic Development Award; and Therapeutic Idea Award. https://cdmrp.health.mil/pubs/press/2025/25alsrppreann	Up to \$2 million, for up to 3 years Dependent upon award mechanism	TBD
		ARTIFICIAL INTELLIGENCE & MACHINE LEARNING (10)		
3.	ARPA-H ImagiNg Data EXchange (INDEX) (ARPA-H) ARPA-H-SOL-25-112	The INDEX program aims to create a platform that seamlessly links data providers, data users, and service providers with high quality images that will enable robust, trustworthy AI tool development for pathology and radiology. The program seeks to increase the number, type, and quality of images available for ML models, as well as boost geographic, racial, and ethnic diversity of images. https://sam.gov/opp/01a4c2bcf976422e83fa18bffbd0a56c/view	Dependent upon proposal and available funds	Solution Summary: 1/23/25 Proposal: 3/27/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARTIFICIAL INTELLIGENCE & MACHINE LEARNING		
4.	Performance and Reliability Evaluation for Continuous modifications and uSEability of AI (PRECISE-AI) (ARPA-H) ARPA-H-SOL-25-113	PRECISE-AI aims to create a suite of self-correction techniques that make it possible to automatically maintain peak model performance of predictive AI components across diverse clinical settings. PRECISE-AI will advance novel approaches to optimally support clinician decision-making and scalably manage the performance of AI Decision Support Tools (AI-DSTs) after their commercial deployment. https://sam.gov/opp/89a99518ba0c409582043a92a2b96a92/view	Dependent upon proposal and award mechanism	Proposal: 1/15/25
5.	NOSI: AI/ML in Pre-Clinical Drug Development for Psychiatric Disorders (NIH/NIMH) NOT-MH-25-050	The central goal of this NOSI is developing and using AI/ML methods to accelerate drug design and optimization for novel psychiatric disease targets. Another goal of this NOSI is to create advanced open-source analytical tools that will be made available to researchers in academia and biotechnology and pharmaceutical companies. https://grants.nih.gov/grants/guide/notice-files/NOT-MH-25-050.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/7/29
6.	PrecisionFDA Generative Artificial Intelligence (GenAI) Community Challenge: Democratizing and Demystifying AI (FDA)	This Challenge aims to: Democratize and demystify GenAI by engaging FDA and public data scientists to help develop innovative GenAI tools and solutions that explore their strengths and limitations within a public health framework; and foster a GenAI user community through hands-on learning by bringing together participants from diverse professional backgrounds to collaborate in helping advance FDA's public health mission. The results of the Challenge will facilitate data sharing and understanding of GenAI, and potentially speed adoption of GenAI across FDA, providing opportunities to enhance processes that ensure the safety and efficacy of regulated products. https://precision.fda.gov/challenges/34	TBD	Proposal: 2/25/25
		AUTISM (4)		
7.	Forecast: FY25 Autism Research Program (ARP) (DoD/CDMRP)	The ARP will support research of exceptional scientific merit and innovation with high impact that focuses on autism. Four awards are anticipated: Career Development Award; Clinical Trial Award; Discovery Award; and Idea Development Award. https://cdmrp.health.mil/pubs/press/2025/25arppreann	Up to \$3 million, for up to 4 years Dependent upon award mechanism	TBD
		BIOENGINEERING (1)		
8.	Hybridizing Biology and Robotics through Integration for Deployable Systems (HyBRIDS) (DoD/DARPA) DARPA-EA-25-02-02	The HyBRIDS ARC opportunity seeks ideas to address the question: How can synthetic and biological components be integrated to enable biohybrid platforms that outperform traditional robotic systems? https://sam.gov/opp/580b34f2b653452badd8ec37590e27ec/view	Up to \$300,000, for up to 1 year	Abstract: 4/7/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOMEDICAL RESEARCH (12)		
9.	Ocular Laboratory for Analysis of Biomarkers (OCULAB) (ARPA-H) ARPA-H-SOL-25-115	The OCULAB program envisions a wearable biomarker measurement system that allows for simultaneous, continuous monitoring of tear biomarkers. Because tears are clear and water-based, they offer a way to measure hormones, vitamins, and proteins with less risk to foul the delicate sensor than blood. Additionally, the OCULAB system aims to provide ultra-precise medication dosing for a personalized treatment via a closed-loop delivery system. The program aims to create a tear-based biomarker measurement system that can be inserted into the tear duct. https://sam.gov/opp/78a735918329482eb8cfd1b0469e6b17/view	Dependent upon proposal and award mechanism	Solution Summary: 1/27/25 Proposal: 4/14/25
10.	Emerging Health Innovators (EHI) Initiative (ARPA-H) ARPA-H-SOL-25-118	The EHI Initiative aims to increase access to government research funding and address health care gaps in the U.S. for early career investigators and community innovators. Track 1, Technology-driven Innovation supports early career investigators in developing innovative health technologies, and has two topics: LS-SAFE -The Lymphatic System's Role in Infectious Disease Makes Us SAFE via Surveillance, Activation, Fluid Return and Elimination; and Advanced Computational Platform for Allogeneic Human Leukocyte Antigen-Matching. Track 2, Community-center Innovation empowers community innovators to develop technology that addresses specific community needs, and has two topics: Disrupting asthma: Empowering community-based organizations to leverage technology and deliver personalized and effective asthma management for children; and Community care for personal well-being: Empowering community-based organizations to leverage technology to deliver personalized environmental monitoring and recommendations. https://sam.gov/opp/549a754f2cc34537b9b8109685a05ea6/view	Dependent upon proposal and award mechanism	Solution Summary: 2/5/25
11.	MTEC Fiscal Year 2025 Multi Topic (MTEC) MTEC-25-Multi-Topic	Medical capabilities play a critical role in each aspect of the future battlespace and must modernize rapidly to maintain Force readiness and increase soldier lethality. MTEC members will be invited to submit enhanced white papers addressing one of the Focus Areas. Anticipated Focus Areas include: Traumatic Brain Injury; Burn Care; Prophylactic to Prevent Infection in Battlefield Wounds from Complex Traumatic Penetrating Injuries in a Far-Forward, Austere Environment; Pathogen Agnostic Countermeasures for the Treatment of Sepsis Caused by Wound Infection; Antivirals for the Prevention and/or Treatment of Endemic and Emerging Infectious Diseases (Non-biothreat Pathogens); Prevention of Endemic Diarrheal Diseases; Knowledge Product Solutions for the Prevention of Infection in Traumatic Penetrating Wounds; Pharmacogenetics; Nutrition; Musculoskeletal injury; and Computer Simulation. https://mtec-sc.org/solicitations/	Dependent upon proposal and award mechanism	Enhanced white paper: 2/10/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOMEDICAL RESEARCH		
12.	ROSES 2024: E.9 Space Biology: Research Studies (NASA) NNH24ZDA001N-SBR	This research reveals how biological systems regulate and sustain growth, metabolism, reproduction, and development in space and how they repair damage and protect themselves from infection and disease. The research emphases of this solicitation fall under two broad categories; Precision Health and Space Crops. Mechanistic understanding of the impact of space-relevant stressors on biological organisms provides insight into adaptation, acclimation, and age-associated disease attributes. https://nspires.nasaprs.com/external/solicitations/summary.do?soldId=%7B6918D3E8-8278-FC53-42DE-D82927D46223%7D&path=&method=init	Dependent upon proposal and award mechanism	Step-1 Proposals: 2/4/25 Step-2 Proposals: 5/6/25
13.	NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed; Basic Experimental Studies with Humans Required; Clinical Trial Required) (NIH) PA-25-301 PA-25-303 PA-25-305	These NOFOs support discrete, specified, circumscribed projects in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. https://grants.nih.gov/grants/guide/pa-files/PA-25-301.html https://grants.nih.gov/grants/guide/pa-files/PA-25-303.html https://grants.nih.gov/grants/guide/pa-files/PA-25-305.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFOs open through 1/7/28
14.	NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed) (NIH) PA-25-302	This NOFO supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. https://grants.nih.gov/grants/guide/pa-files/PA-25-302.html	Up to \$50,000 per year, for up to 2 years	Multiple deadlines; NOFO open through 1/7/28
15.	NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed/Required/Basic Experimental Studies with Humans Required) (NIH) PA-25-304 PA-25-306 PA-25-307	These NOFOs promote exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. https://grants.nih.gov/grants/guide/pa-files/PA-25-304.html https://grants.nih.gov/grants/guide/pa-files/PA-25-306.html https://grants.nih.gov/grants/guide/pa-files/PA-25-307.html	Up to \$275,000, for up to 2 years	Multiple deadlines; NOFOs open through 1/7/28



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOMEDICAL RESEARCH		
16.	Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed) (NIH/NCI/NIDCR) PAR-25-346	This NOFO encourages submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility. https://grants.nih.gov/grants/guide/pa-files/PAR-25-346.html	Up to \$275,000, for up to 2 years	Multiple deadlines; NOFO open through 11/16/27
		CANCER (48)		
17.	NOSI: Mechanisms Driving Obesity and Prostate Cancer Risk (NIH/NCI) NOT-CA-25-002	The purpose of this NOSI is to promote studies examining the mechanisms by which obesity drives aggressive prostate cancer (PCa) risk. The biologic mechanisms driving both overall and aggressive PCa are uncertain. The identification of differences in the mechanisms driving aggressive vs. overall disease are critical to optimizing clinical care among men who develop the disease. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-25-002.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/7/28
18.	NOSI: Research on rare cancers across the cancer control continuum (NIH/NCI) NOT-CA-25-010	This purpose of this NOSI is to stimulate observational and intervention research focused on rare cancers that is within the mission of DCCPS. DCCPS has several broad areas of interest: development and validation of methods, technologies, and tools in surveillance, statistics, epidemiology, health care delivery, and the behavioral sciences; identification of modifiable risk factors or host susceptibility factors associated with cancer etiology, cancer prevention, and treatment outcomes; and clinical and translational science to reduce risk, incidence, and death from cancer, as well as to enhance the quality of life for cancer survivors. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-25-010.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/7/28
19.	NOSI: Survivorship Research for People Living with Advanced and Metastatic Cancers (NIH/NCI) NOT-CA-25-024	The NCI seeks applications proposing observational or intervention studies focused on survivorship for people living with advanced and metastatic cancers. Research interests include studies of: Clinical, genomic, and lifestyle factors; Trajectories of physiological and psychological symptoms; Innovative models of health care delivery; Prognostic awareness, uncertainty, and communication between providers, survivors, and caregivers; Strategies to address care needs for people from populations that experience health or care disparities. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-25-024.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/7/28
20.	Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed) (NIH/NCI) PAR-25-325	This NOFO supports research to investigate and mitigate challenges in clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as "liquid biopsies", or other biospecimens as described in this NOFO. https://grants.nih.gov/grants/guide/pa-files/PAR-25-325.html	Up to \$250,000 per year, for up to 5 years	Multiple deadlines; NOFO open through 9/10/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
21.	Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed) (NIH/NCI) PAR-25-336	This NOFO is designed to enable the translation of nanotechnology-based cancer interventions relying on nanoparticle formulations and/or nano-devices. Through the TTNCI initiative, the NCI encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. https://grants.nih.gov/grants/guide/pa-files/PAR-25-336.html	Up to \$475,000 per year, for up to 4 years	Multiple deadlines; NOFO open through 11/15/27
22.	Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional/Not Allowed) (NIH/NCI) PAR-25-337 PAR-25-338	These NOFOs aim to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. They specify a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. https://grants.nih.gov/grants/guide/pa-files/PAR-25-337.html https://grants.nih.gov/grants/guide/pa-files/PAR-25-338.html	Up to \$499,000 per year, for up to 5 years	Multiple deadlines; NOFOs open through 11/5/27
23.	Basic and Clinical Cancer Research: Molecular and Cellular Analysis Technologies and Biospecimen Science Technologies (R61/R33 Clinical Trial Not Allowed) (NIH/NCI) RFA-CA-25-001 (R61) RFA-CA-25-002 (R33) RFA-CA-25-003 (R61) RFA-CA-25-004 (R33)	These NOFOs solicit applications proposing exploratory research projects focused on highly innovative technologies, both novel and those requiring further development, for basic and clinical cancer research. Highly innovative technologies are sought that offer capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology; and for maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-001.html (R61) https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-002.html (R33) https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-003.html (R61) https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-004.html (R33)	Up to \$150,000 per year, for up to 3 years (R61) Up to \$300,000 per year, for up to 3 years (R33)	Multiple deadlines; NOFOs open through 10/3/25
24.	Addressing Barriers to Healthcare Transitions for Survivors of Childhood and Adolescent Cancers (R01 Clinical Trial Optional) (NIH/NCI) RFA-CA-25-019	The goal of this opportunity is to support the development and testing of interventions and strategies that promote high-quality transitional care and continued engagement of survivors of childhood and adolescent cancers to ensure these survivors receive appropriate surveillance and care into adulthood. https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-019.html	Up to \$499,000 per year, for up to 5 years	Letter of intent: 9/17/25 Proposal: 10/17/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
25.	Forecast: FY25 Ovarian Cancer Research Program (DoD/CDMRP)	Six awards are anticipated: Clinical Trial Award; Clinical Trial Translational Endpoints Award; Investigator-Initiated Research Award; Ovarian Cancer Academy - Early-Career Investigator Award; Ovarian Cancer Clinical Trial Academy - Early-Career Investigator Award; and Pilot Award. All applications must address one or more of the areas of emphasis . https://cdmrp.health.mil/pubs/press/2025/25ocrppreann	Up to \$2 million, for up to 4 years Dependent upon award mechanism	TBD
		CARDIOVASCULAR AND PULMONARY HEALTH (5)		
26.	NOSI: Cardiorespiratory and Sleep Complications of the Muscular Dystrophies (NIH/NHLBI) NOT-HL-24-036	The purpose of this NOSI is to enhance basic, translational, and clinical research in the cardiorespiratory and sleep complications associated with muscular dystrophies. The goals include elucidating phenotypes, optimizing metrics for early diagnosis, refining therapies such as gene therapy delivery to cardiac and respiratory muscles, and exploring mechanisms and treatment strategies for sleep-disordered breathing (SDB). https://grants.nih.gov/grants/guide/notice-files/NOT-HL-24-036.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOSI open through 2/5/28
27.	NOSI: Bold New Bioengineering Research for Heart, Lung, Blood and Sleep Disorders (NIH/NHLBI) NOT-HL-24-037	This NOSI invites discovery- and design-driven bioengineering research ideas that are important across the Institute and critical for future hypothesis-generating projects. Notably, this program emphasizes first-generation prototype development and initial feasibility studies. The NHLBI is interested in the development of new ideas for diagnostics, therapeutics, surgical technologies, artificial intelligence/machine learning/computational modeling tools, smart biomaterials for self-adjusting implants, molecular imaging, synthetic biology, and nanotechnologies, as applied to HLBS-related issues. https://grants.nih.gov/grants/guide/notice-files/NOT-HL-24-037.html	Up to \$275,000, for up to 2 years	Multiple deadlines; NOSI open through 1/7/28
28.	Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required) (NIH/NHLBI) PAR-25-028	This NOFO supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. https://grants.nih.gov/grants/guide/pa-files/PAR-25-028.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 9/11/25
29.	Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required) (NIH/NHLBI) PAR-25-029	This NOFO supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. https://grants.nih.gov/grants/guide/pa-files/PAR-25-029.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 9/11/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CARDIOVASCULAR AND PULMONARY HEALTH		
30.	NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional) (NIH/NHLBI) PAR-25-032	This NOFO supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. https://grants.nih.gov/grants/guide/pa-files/PAR-25-032.html	Up to \$450,000, for up to 3 years	Multiple deadlines; NOFO open through 1/7/27
		CHRONIC PAIN & PAIN MANAGEMENT (1)		
31.	HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed) (NIH) PAR-25-154	This NOFO supports pilot projects to identify new druggable targets for pain within the understudied druggable proteome. This NOFO is intended to jumpstart research on understudied proteins within the context of pain and pain management and provide applicants with sufficient funding to perform basic biochemical and/or biological work to further the characterization of understudied proteins to identify new druggable targets for pain. https://grants.nih.gov/grants/guide/pa-files/PAR-25-154.html	Up to \$100,000, for up to 1 year	Multiple deadlines; NOFO open through 7/16/26
		COGNITIVE AND BRAIN HEALTH (5)		
32.	NOSI: Human Cell Biology of Alzheimer's Disease Genetic Variants (NIH/NIA) NOT-AG-24-039	The goal of this NOSI is to encourage research that assesses the function of AD genetic variants and other age- and disease-modifying factors contributing to AD using human cell reprogramming and genomic editing approaches. The impact of aging and approaches to induce or recapitulate brain aging in these human cell models should be considered, as aging is a major risk factor for AD. https://grants.nih.gov/grants/guide/notice-files/NOT-AG-24-039.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 11/16/27
33.	Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21/R01 Clinical Trial Optional) (NIH/NIA/NINDS) PAR-25-331 (R21) PAR-25-332 (R01)	These NOFOs invite applications proposing new tests, animal models, techniques, etc. to advance research on AD/ADRD that need additional preliminary data with broader dissemination to establish them for more general use in this research field. The priority topics will be announced through a series of Notices published subsequently. https://grants.nih.gov/grants/guide/pa-files/PAR-25-331.html (R21) https://grants.nih.gov/grants/guide/pa-files/PAR-25-332.html (R01)	Up to \$275,000, for up to 2 years (R21) Dependent upon proposal, for up to 5 years (R01)	Multiple deadlines; NOFOs open through 11/16/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH		
34.	Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for AD/ADRD (R01 Clinical Trial Not Allowed) (NIH/NIA) PAR-25-374	This NOFO invites applications that combine computational and experimental approaches to enable rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be efficacious in AD/ADRD. This initiative will also support preclinical testing of repurposable or investigational drug candidates in combination with non-pharmacologic interventions leading to robust translational outcomes. https://grants.nih.gov/grants/guide/pa-files/PAR-25-374.html	Up to \$1 million per year, for up to 5 years	Multiple deadlines; NOFO open through 3/7/28
		COMMUNICATION DISORDERS (5)		
35.	NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required) (NIH/NIDCD) PAR-25-343	This NOFO supports a cooperative agreement between an NIDCD Project Scientist and an Investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, is intended to formally establish efficacy, or has potentially higher risks to participants. https://grants.nih.gov/grants/guide/pa-files/PAR-25-343.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 10/18/27
36.	NIDCD Research Grants for Translating Basic Research into Clinical Practice (R01 Clinical Trial Optional) (NIH/NIDCD) RFA-DC-25-002	This NOFO provides an avenue for basic scientists, clinicians, and clinical scientists to jointly initiate and conduct research projects that translate basic research findings into clinical practice for better human health. The scope of this NOFO includes a range of activities that will impact the diagnosis, treatment, and prevention of disorders within NIDCD's scientific mission. https://grants.nih.gov/grants/guide/rfa-files/RFA-DC-25-002.html	Up to \$500,000 per year, for up to 5 years	Multiple deadlines; NOFO open through 10/12/27
37.	In Vivo High-Resolution Imaging for Inner Ear Visualization (U01 Clinical Trial Required/R01 Clinical Trial optional) (NIH/NIDCD) RFA-DC-25-003 (U01) RFA-DC-25-005 (R01)	These NOFOs support the development of in vivo high-resolution structural and functional imaging technologies for the living human inner ear. Proposed projects should focus on improving the resolution of current imaging techniques or developing new imaging techniques that can visualize inner ear structures in vivo with significantly greater detail and accuracy than currently possible. https://grants.nih.gov/grants/guide/rfa-files/RFA-DC-25-003.html (U01) https://grants.nih.gov/grants/guide/rfa-files/RFA-DC-25-005.html (R01)	Up to \$500,000 per year, for up to 5 years	Multiple deadlines; NOFOs open through 10/1/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COMMUNICATION DISORDERS		
38.	NIDCD Research Opportunities for New Investigators to Promote Workforce Development (R01 Clinical Trial Optional) (NIH/NIDCD) RFA-DC-25-004	This NOFO solicits applications that propose independent research projects that are within the scientific mission areas of the NIDCD. This program is intended to support Early Stage and New Investigators from diverse backgrounds, including individuals from groups underrepresented in the health-related sciences. https://grants.nih.gov/grants/guide/rfa-files/RFA-DC-25-004.html	Up to \$500,000 per year, for up to 5 years	Multiple deadlines; NOFO open through 10/6/26
		DIVERSITY AND INCLUSION (1)		
39.	NIAID, NIDDK, NIDA, and NIAAA Research Opportunities for New and "At-Risk" Investigators (R01 Clinical Trial Optional) (NIH) PA-25-249	This NOFO encourages New and 'At-risk' Investigators from diverse backgrounds to work with their institutions to submit applications for research projects within the mission of NIAID, NIDDK, NIDA, or NIAAA. https://grants.nih.gov/grants/guide/pa-files/PA-25-249.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 9/7/25
		ENDOCRINE & METABOLIC DISEASE (5)		
40.	NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required/Not Allowed) (NIH/NIDDK) PA-25-147 PAR-25-089	These NOFOs invite applications for investigator-initiated, high-risk multi-center observational studies involving more than one clinical center. Proposed studies should be hypothesis-driven and focus on a disease relevant to the mission of NIDDK. Clinical trials must also have the potential to change clinical practice and/or public health. https://grants.nih.gov/grants/guide/pa-files/PA-25-147.html https://grants.nih.gov/grants/guide/pa-files/PAR-25-089.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFOs open through 11/5/26
41.	High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional) (NIH/NIDDK) PAR-25-277	The interdisciplinary approach encouraged by this NOFO is envisioned to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community. This NOFO seeks novel approaches in areas that address specific knowledge gaps, scientific opportunities, new technologies, data generation, or research methods that will advance the area in significant ways designed to accelerate scientific progress in the understanding, treatment, and prevention of diseases, including the promotion of health equity, within the mission of the NIDDK. https://grants.nih.gov/grants/guide/pa-files/PAR-25-277.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 10/15/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ENDOCRINE & METABOLIC DISEASE		
42.	Continuation of the NIDDK Hematology Central Coordinating Center (U24 Clinical Trial Not Allowed) (NIH/NIDDK) RFA-DK-25-023	The HCC will (1) provide central administrative support for the NIDDK CCEH Program, (2) develop and execute a communication and promotion plan to disseminate all CCEH resources, news, seminars, funding opportunities and activities, (3) develop and implement a multipronged education/enrichment plan for junior researchers and students interested in conducting hematology research to maximize national outreach and impact, (4) create and administer an Opportunity Pool of funds to support national and regional enrichment programs, a national Pilot and Feasibility Grant program, and other innovative programs to address gaps in the field and promote collaboration. https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-023.html	Up to \$1.3 million per year, for up to 5 years	Letter of intent: 2/18/25 Proposal: 3/18/25
43.	NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed) (NIH/NIDDK) RFA-DK-26-006	Applications should be focused on major scientific challenges and have the potential to produce an unusually high impact on diseases and conditions that are central to the mission of these NIDDK;s Divisions of Diabetes, Endocrinology and Metabolic Diseases; and Digestive Diseases and Nutrition. To be considered responsive to this initiative, the proposed research should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigator's research program or elsewhere. https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-26-006.html	Up to \$500,000 per year, for up to 5 years	Letter of intent: 6/18/25 Proposal: 7/18/25
		ENERGY SCIENCE (1)		
44.	Systems Biology Research to Advance Bioenergy Crop Production (DoE) DE-FOA-0003453	This NOFO aims to build upon the advances made since previous BER investments in this area, seeking to apply systems biology and omics technologies to map the complex networks and molecular mechanisms of bioenergy crop growth, development, and metabolism for sustainable and resilient bioenergy crop production. Understanding the multi-organismal "biofuel crop+soil+microbe ecosystem" presents a unique challenge, which is further complicated by environmental impacts. https://science.osti.gov/ber/-/media/grants/pdf/foas/2025/DE-FOA-0003453_v3.pdf	Up to \$3 million per year, for up to 5 years	Pre-application: 1/17/25 Proposal: 3/26/25
		GENOMICS (1)		
45.	Supporting Talented Early Career Researchers in Genomics (R01 Clinical Trial Optional) (NIH/NHGRI) RFA-HG-25-009	This NOFO is intended to identify and support research projects by exceptionally promising Early Stage Investigators with a long-term career interest in pursuing innovative research in genomics. This opportunity is open to research in all areas relevant to the mission of NHGRI, including genomic sciences, genomic medicine, genomic data science, and ethical, legal, and social implications (ELSI) of genomics. https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-25-009.html	Up to \$400,000 per year, for up to 4 years	Multiple deadlines; NOFO open through 2/26/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HEALTH IT & DATA (5)		
46.	Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed) (NIH/NHLBI) PAR-25-056	The NOFO aims to stimulate the use of existing human datasets to investigate novel scientific ideas, and/or generate new models, systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. https://grants.nih.gov/grants/guide/pa-files/PAR-25-056.html	Up to \$75,000 per year, for up to 2 years	Multiple deadlines; NOFO open through 1/7/26
47.	NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed) (NIH/NEI) PAR-25-357	This NOFO supports secondary data analyses using existing data collected from humans participating in vision-related clinical trials, epidemiologic, and other clinical research studies or represented in clinical and health care database resources. This NOFO may be used to develop new statistical methodologies or test hypotheses using existing data, but this NOFO must not be used to support the collection of new data. https://grants.nih.gov/grants/guide/pa-files/PAR-25-357.html	Up to \$275,000, for up to 2 years	Multiple deadlines; NOFO open through 10/16/27
48.	D-START: Data Science Track Award for Research Transition (D/START) (R03-Clinical Trial Optional) (NIH/NIDA) PAS-25-236	This NOFO seeks to support investigators interested in applying cutting-edge data science techniques to address timely and challenging research questions related to substance use and/or SUD in all areas of research supported by NIDA. https://grants.nih.gov/grants/guide/pa-files/PAS-25-236.html	Up to \$100,000 per year, for up to 2 years	Multiple deadlines; NOFO open through 9/7/27
49.	Deriving Common Data Elements from Real-World Data for Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (U24 Clinical Trial Not Allowed) (NIH/NIA) RFA-AG-25-001	The CDEs will foster data harmonization and interoperability across and among NIA studies that involve disparate and unaligned data fields and RWD. By reducing the efforts required for data harmonization in using studies and RWD for cross-sectional and longitudinal analysis, this NOFO may enable researchers to utilize studies data and RWD more efficiently and produce real-world evidence (RWE) in a timely manner with longitudinal data from NIA-funded studies and RWD. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-001.html	Up to \$3.75 million per year, for up to 5 years	Letter of intent: 1/14/25 Proposal: 2/14/25
50.	Complement-ARIE New Approach Methodologies (NAMs) Data Hub and Coordinating Center (U24 Clinical Trial Optional) (NIH Common Fund) RFA-RM-24-013	This NOFO will support Complement-ARIE by providing a centralized data hub, building a searchable repository for various NAMs data types, establishing standards for data reporting and model credibility, developing and implementing an Integrated Testing Strategies (ITS), developing strategies for interoperability, sustainability data reuse, and developing tools for data analytics, dissemination, and sharing. https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-24-013.html	Dependent upon proposal, for up to 5 years	Letter of intent: 2/10/25 Proposal: 3/10/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HIV/AIDS (5)		
51.	Forecast: Alcohol-HIV/AIDS Program Project Comorbidities, Coinfections, and Complications Research: Intervention and Cross-Cutting Foundational Research (Po1 Clinical Trial Optional) (NIH/NIAAA) NOT-AA-25-002	This NOFO will solicit applications for research on the intersection of alcohol and HIV/AIDS. https://grants.nih.gov/grants/guide/notice-files/NOT-AA-25-002.html	Up to \$1 million per year	Estimated post date: 7/1/25 Estimated proposal date: 9/25/25
52.	Planning for Product Development Strategy (R34 Clinical Trial Not Allowed) (NIH/NIAID) PAR-25-099	This NOFO supports the development of a comprehensive and well-defined product development strategy for next-generation treatments for HIV and HIV-associated comorbidities, coinfections and complications and preventive strategies for HIV, as well as facilitating the translation of research findings into drug products that enables submission of an Investigational New Drug (IND) application to the FDA. https://grants.nih.gov/grants/guide/pa-files/PAR-25-099.html	Up to \$225,000 per year, for up to 1 years	Multiple deadlines; NOFO open through 12/4/26
53.	Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01/R21 Clinical Trial Not Allowed) (NIH/NIAID) PAR-25-315 (R01) PAR-25-316 (R21)	These NOFOs support research to elucidate how HIV-induced immunometabolic alterations, in a host suppressed on combination antiretroviral therapy, impact the immune response and increase risk for poor outcomes due to a second, potentially long-term, infection. They aim to support research to define how HIV-driven alterations to immunometabolism affect immune cell regulation, cell-cell interactions, response to treatment, and, ultimately, TB and HBV disease progression. https://grants.nih.gov/grants/guide/pa-files/PAR-25-315.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-316.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Multiple deadlines; NOFOs open through 1/7/28
54.	Ex Vivo Models for Studies at the Intersection of HIV and Addictive Substance Use (R01 Clinical Trial Not Allowed) (NIH/NIDA) RFA-DA-25-074	This NOFO invites grant applications aimed at elucidating neuroimmune and neuronal-glia pathophysiological mechanisms underlying the interaction between addictive substances and HIV-associated neurological disorders (HAND) using ex vivo culturing platforms derived from human induced pluripotent stem cells (hiPSC). https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-074.html	Dependent upon proposal, for up to 5 years	Letter of intent: 7/13/25 Proposal: 8/13/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE (1)		
55.	Broad Spectrum Products Against Multiple Neurotoxin Botulinum Serotypes (R61/R33 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-24-080	This NOFO supports the development of improved products for treating Botulinum Neurotoxin (BoNT) intoxication. Development of products that can reverse BoNT intoxication are highly encouraged. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-080.html	Up to \$300,000 per year, for up to 2 years (R61) Up to \$750,000 per year, for up to 3 years (R33)	Letter of intent: 4/2/25 Proposal: 5/2/25
		MATERNAL AND PEDIATRIC HEALTH (2)		
56.	Leveraging Network Infrastructure to Conduct Innovative Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities (UG3/UH3 - Clinical Trial Optional) (NIH/NICHD/ORWH) PAR-25-311	The purpose of this NOFO is to leverage NICHD clinical research network infrastructure relevant to infants, children, women, pregnant and lactating individuals, and persons with disabilities to conduct innovative, multisite, investigator-initiated clinical trials and observational studies. This NOFO provides an opportunity to leverage NICHD clinical research network infrastructure as a platform for investigator-initiated innovative hypotheses by any investigator in the extramural community. https://grants.nih.gov/grants/guide/pa-files/PAR-25-311.html	Up to \$6.25 million, for up to 7 years	Multiple deadlines; NOFO open through 11/15/27
		MATERNAL AND PEDIATRIC HEALTH		
57.	Early Immune System Development and Ontogeny (R01 Clinical Trial Optional) (NIH/NICHD) PAR-25-362	The purpose of this NOFO is to further elucidate the mechanisms of early immune development in utero, during the early post-natal period and during early childhood in neonates, infants, and children and adolescents with or without in-utero exposure to HIV or ART. This initiative aims to understand intricate mechanisms of immune cells at the maternal-fetal interface, T and B cell development and maturation in offspring, and local immune responses and the role of systemic immunity. https://grants.nih.gov/grants/guide/pa-files/PAR-25-362.html	Up to \$400,000 per year, for up to 4 years	Multiple deadlines; NOFO open through 1/7/29
		MEDICAL COUNTERMEASURES (1)		
58.	Development of Radiation/Nuclear Medical Countermeasures (MCMs) And Biodosimetry Devices (NIH/NIAID) BAA-75N93024R00020	The first goal is to develop safe and effective MCMs to mitigate and/or treat normal tissue injuries arising from exposure to ionizing radiation from a radiological or nuclear incident, thereby leading to a reduction in radiation-associated mortality and/or major morbidities. MCMs are not expected to be effectively mobilized for use within the first day; therefore, MCMs must be efficacious 24 hours or later post-exposure. The second goal is to advance biodosimetry biomarkers and/or devices to inform triage and treatment strategies for use during a radiation public health emergency. https://sam.gov/opp/a4650159a8bf4733a63b2b7d22d5ff84/view	TBD	Proposal: 3/19/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MENTAL HEALTH (13)		
59.	NOSI: Molecular and Cellular Computational Tools Supporting Fundamental Neuroscience Research in Health, Mental Illness and Developmental Processes (NIH/NIMH) NOT-MH-25-045	This NOSI invites rigorous, hypothesis-driven studies that integrate the development of biophysically based models of neuronal and glial processes with an experimental component to test model predictions. It supports studies conducted in vitro, ex vivo, and in vivo toward the goal of uncovering mechanistic links across biological scales. To promote this interdisciplinary research, collaborations between investigators with complementary theoretical/computational and experimental expertise are essential. https://grants.nih.gov/grants/guide/notice-files/NOT-MH-25-045.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/9/28
60.	Innovative Mental Health Services Research Not Involving Clinical Trials (R01/R34 Clinical Trial Not Allowed) (NIH/NIMH) PAR-25-283 (R01) PAR-25-284 (R34)	These NOFOs encourage innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. https://grants.nih.gov/grants/guide/pa-files/PAR-25-283.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-284.html (R34)	Dependent upon proposal, for up to 5 years (R01) Up to \$450,000, for up to 3 years (R34)	Multiple deadlines; NOFOs open through 11/16/27
		MICROGRAVITY RESEARCH (2)		
61.	Technology Advancement and Applied Research Leveraging the ISS National Lab, Cycle 1 (NASA) NLRA 2025-5	This NLRA solicits flight proposals that seek to advance technology for use-inspired R&D in space across a broad range of existing or emerging technology areas. Technology areas include: chemical and material synthesis in space, translational medicine, and advanced materials testing. Potential translational medicine topics include: validation of accelerated disease models using cell- or organism-based models, analyzing macromolecular structures for structure-based drug design, and demonstration of novel drug delivery and diagnostic devices. https://issnationallab.org/opportunities/nlra-2025-5-technology-advancement-and-applied-research-cycle1/#1710789920927-307da5f5-f7640572-85ba	Dependent upon proposal and available funds	Concept Summary: 3/3/25
62.	NSF/CASIS Transport Phenomena Research at the International Space Station to Benefit Life on Earth (NSF/CASIS) NSF 25-529	The solicitation seeks to increase use of the ISS National Lab for fluid dynamics, particulate and multiphase processes, combustion and fire systems, thermal transport processes, and nanoscale interactions studies to benefit applications or industries on Earth, to promote ISS as well as new and existing facility/technology utilization. Ideal proposals will describe a commercial, civil, or academic project to achieve research or technology development objectives that will directly impact areas including: Carbon emissions and capture; Manufacturing; Medical devices and pharmaceuticals; Microfluidics and nanofluidics; and Disaster prevention and mitigation. https://new.nsf.gov/funding/opportunities/nsfcasis-transport-phenomena-research-international-space/nsf25-529/solicitation	Up to \$400,000, for up to 4 years	Feasibility Review Form: 2/6/25 Proposal: 4/10/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		RARE DISEASES (1)		
63.	Rare Disease AI/ML for Precision Integrated Diagnostics (RAPID) Proposers' Day (ARPA-H) ARPA-H-SN-25-124	The RAPID program aims to transform the diagnosis of rare and ultra-rare diseases by developing highly accurate AI-based detection models. RAPID seeks to develop provider-facing tools that prioritize data interoperability and integration into existing clinical workflows, ensuring scalability across health care organizations. https://arpa-h.gov/research-and-funding/programs/rapid https://sam.gov/opp/9f2829bc90334594974c63674aca430f/view	Dependent upon proposal and award mechanism	Proposers' Day: 1/23/25 Solution Summary: 2/14/25 Patients' Day: 2/25/25
		SMALL BUSINESS DEVELOPMENT (5)		
64.	NASA SBIR and STTR Phase I FY2025 (NASA) 80NSSCFY25SBIRPhaseI 80NSSCFY25STTRPI80NSSCFY25STTRPI	Topics include: Oxygen Compatible Habitation Solutions for Exploration Environments; Long-Duration Exploration PLSS Capabilities; In Situ Sample Preparation and Analysis for Biological and Physical Sciences in a Microgravity Environment; and Biomanufacturing for Space Missions: Harnessing Microbial Communities for Sustainable Production in Moon and Mars Environments. https://sam.gov/opp/83b8ac08aa6c4612bfa584365d2ad61e/view https://sam.gov/opp/639c1bfb28ba4e21a041ae06c914eccf/view	Up to \$150,000	Proposal: 3/10/25
65.	FY 2025 Phase I Release 2 (DoE) DE-FOA-0003504	Topics of this DoE SBIR/STTR release are anticipated to include: Plastic Circularity and Bioenergy Feedstock Logistics Improvements. https://science.osti.gov/-/media/grants/pdf/foas/2025/DE-FOA-0003504-0001-for-publication.pdf	Up to \$250,000, for up to 1 year (Phase I) Up to \$1.6 million (Phase II)	Letter of intent: 1/14/25 Proposal: 2/26/25
66.	DHA 2025.1 SBIR and STTR (DoD/DHA) DoD SBIR 2025.1 DoD STTR 2025.A	Topics in this SBIR and STTR release include: Platelet Contractility / Retraction Measurement Device; A Mobile Application for Prediction of Blast Overpressure Exposure in Civilian and Military Operations; and Development of Organoid Screening Tool for High-Throughput Compound Screening to Be Used in Military-Relevant Exposures. https://www.dodsbirsttr.mil/topics-app/	Up to \$250,000, for up to 6 months (Phase I) Up to \$1.3 million, for up to 2 years (Phase II)	Proposal: 2/5/25
		SOCIAL DETERMINANTS OF HEALTH (1)		
67.	Transformative Research to Address Health Disparities and Advance Health Equity (U01 Clinical Trial Optional) (NIH) RFA-NR-25-003	This NOFO solicits applications to support unusually innovative intervention research addressing SDOH which would have a major impact on preventing, reducing, or eliminating health disparities and advancing health equity. Projects should clearly demonstrate a compelling potential to produce a major impact on advancing NIH's commitment to addressing SDOH. https://grants.nih.gov/grants/guide/rfa-files/RFA-NR-25-003.html	Up to \$500,000 per year, for up to 5 years	Letter of intent: 1/29/25 Proposal: 2/28/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SUBSTANCE USE DISORDER (5)		
68.	Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional) (NIH/NIDA) PAR-25-101	This award is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of SUDs. It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio that has the potential to transform SUD research. The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking. https://grants.nih.gov/grants/guide/pa-files/PAR-25-101.html	Up to \$275,000, for up to 2 years	Multiple deadlines; NOFO open through 8/11/27
69.	Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional) (NIH/NIDA) PAR-25-328	This NOFO supports research to advance the development of safe and effective medications for the treatment of SUD. It includes preclinical and/or clinical research projects, from lead optimization all the way Phase I, Phase II, and Phase III clinical trials. The goal is to fund studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. https://grants.nih.gov/grants/guide/pa-files/PAR-25-328.html	Up to \$5 million per year, for up to 3 years	Multiple deadlines; NOFO open through 8/11/25
70.	Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional) (NIH/NIDA) PAR-25-329	This NOFO supports research that will fast-track the discovery and development of medications to prevent and treat SUDs and overdose. Application may include preclinical or clinical research studies that will have high impact and quickly yield the necessary results to advance closer to or to FDA approval. The compounds to be evaluated can be small molecules or biologic and may focus on the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications. https://grants.nih.gov/grants/guide/pa-files/PAR-25-329.html	Up to \$3 million per year, for up to 5 years	Multiple deadlines; NOFO open through 8/11/25
71.	HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional) (NIH) RFA-DA-25-077 (R33) RFA-DA-25-078 (R61/R33)	These NOFOs support action-oriented research that accelerates the translation of research to practice to address the overdose crisis. There remains an urgent need for research to address understudied areas of opportunity, particularly addressing the fundamental barriers or facilitators to reducing overdose deaths at the individual, provider, organizational, community, or system levels. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-077.html (R33) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-078.html (R61/R33)	Up to \$300,000 per year, for up to 2 years (R61) Up to \$750,000 per year, for up to 5 years (R33)	Letter of intent: 2/20/25 Proposal: 3/20/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		THERAPEUTICS (2)		
72.	Draft: Proactive Solutions for Prolonging Resilience (PROSPR) (ARPA-H) ARPA-H-SOL-25-125	This program aims to identify biochemical and physiological markers and develop assessment tools that will allow researchers to better understand and target the underlying causes of age-related disease. To achieve this goal, PROSPR will pioneer in-home data collection and clinical trial protocols that can assess age-associated health outcomes in just three years instead of decades of study, accelerating the availability of new therapies. https://sam.gov/opp/05eb7371faa34a47990829b33212ce1a/view https://sam.gov/opp/50dc418ee8664289a7e4f15f7fe954e9/view	Dependent upon proposal and award mechanism	Proposers' Day: 1/24/25 Solution Summary: 2/10/25 Proposal: 3/24/25
73.	Translational Efforts and Network Resource Access to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (X01, Clinical Trial Not Allowed/U01 - Clinical Trial Optional) (NIH/NINDS) PAR-25-326 (X01) PAR-25-327 (U01)	The Ultra-Rare Gene-Based Therapy (URGenT) network supports IND-enabling studies and planning activities for FIH clinical testing of gene-based or transcript-directed therapeutics for ultra-rare neurological or neuromuscular disorders. These NOFOs aim to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated POC data, as well as provide a mechanism to access CROs/CMOs and SMEs to support planning, manufacturing, and limited nonclinical therapeutic development efforts and other IND-enabling activities. https://grants.nih.gov/grants/guide/pa-files/PAR-25-326.html (X01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-327.html (U01)	Resource support only (X01) Dependent upon proposal, for up to 3 years (U01)	Multiple deadlines; NOFOs open through 1/31/28
		TUBEROUS SCLEROSIS COMPLEX (3)		
74.	Forecast: FY25 Tuberos Sclerosis Complex Research Program (DoD/CDMRP)	Three awards are anticipated in the TSCRCP: Clinical Translational Research Award; Exploration - Hypothesis Development Award; and Idea Development Award. All applications must be relevant to one or more of the focus areas . https://cdmrp.health.mil/pubs/press/2025/25tscrppreann	Up to \$1.15 million, for up to 3 years Dependent upon award mechanism	TBD
		VISION HEALTH (4)		
75.	NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed) (NIH/NEI) PAR-25-335 (R61/R33) PAR-25-363 (R33)	These NOFOs support the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. The ultimate goal of this program is to make new technological, biological and pharmacological resources available to clinicians and their patients. https://grants.nih.gov/grants/guide/pa-files/PAR-25-335.html (R61/R33) https://grants.nih.gov/grants/guide/pa-files/PAR-25-363.html (R33)	Up to \$500,000 per year, for up to 2 years (R61) Up to \$1 million per year, for up to 5 years (R33)	Letter of intent: 1/16/25 Proposal: 2/16/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		VISION HEALTH		
76.	Advancing Vision Health Equity through Multi-level Interventions and Community-Engaged Research (R01 - Clinical Trial Optional) (NIH/NEI/NIMHD) RFA-EY-25-002	This NOFO requests applications that aim to implement and evaluate multi-level interventions and community engaged research in advancing vision equity. It supports research directed at preventing, reducing, or eliminating disparities in eye and vision health. https://grants.nih.gov/grants/guide/rfa-files/RFA-EY-25-002.html	Up to \$1 million per year, for up to 5 years	Letter of intent: 2/3/25 Proposal: 3/3/25
77.	Forecast: FY25 Vision Research Program (DoD/CDMRP)	The Mentored Clinical Research Award is anticipated. Additional forecasts to be posted. Applications submitted to the FY25 VRP must address one or more focus areas: Understand and treat eye injury or visual dysfunction as related to military exposure; Restore visual function after military exposure-related vision loss or severe visual impairment; Diagnose, stabilize, and treat eye injuries in austere environments and prolonged care settings. https://cdmrp.health.mil/pubs/press/2025/25vrppreann	Up to \$75,000, for up to 18 months	TBD
		WOMEN'S HEALTH (3)		
78.	NOSI: Innovative Interdisciplinary Research on Female Reproductive Aging (NIH/NIA) NOT-AG-24-074	NIA is issuing this notice to encourage innovative interdisciplinary research on the molecular, cellular, and physiological processes involved in female reproductive aging, with the goal to identify and understand key biological pathways involved in aging associated health outcomes in women across the lifespan. Interdisciplinary research that integrates knowledge, expertise, and perspectives from different disciplines may help to give a more complete understanding of the biological drivers of female reproductive aging, as well as provide novel insights into the complexity of overall aging in females. https://grants.nih.gov/grants/guide/notice-files/NOT-AG-24-074.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/8/28
79.	Model Continuums of Care Initiative (MCCI) to Advance Health Equity and End Health Disparities Among Women and Girls in Racial/Ethnic Minority and Other Underserved Communities (U34 Clinical Trials Required) (NIH) RFA-AA-24-012	MCCI is a multi-ICO dissemination and implementation science initiative to advance racial equity and end health disparities in racial/ethnic minority women and girls of reproductive age. This concept proposes a continuum of care approach that integrates preventive health services, primary care, behavioral health, integrative care, and cardiopulmonary and endocrine specialties to fully address health care needs in each of these domains, and to have maximum impact on the overall health and well-being of racial and ethnic minority and other underserved women and girls. https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-24-012.html	Up to \$600,000, for up to 3 years	Letter of intent: 1/19/25 Proposal: 2/19/25





Recurring Opportunities

January 8, 2025

<https://www.g2gconsulting.com/gbg-reporting-service/>

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (4)		
80.	Office-Wide Innovative Solutions Opening for Resilient Systems Office (RSO) ARPA-H-SOL-24-103	RSO seeks solution summaries and proposals that drive innovations to enhance the adaptability, reliability, and interoperability of the health ecosystem. The following interest areas categorize the ground-breaking research we seek to support: Sociotechnical System Innovation; Health Ecosystem Integration; and Adaptive & Antifragile Solutions. https://sam.gov/opp/76679cd8810f40229694c60c0a593302/view	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25
81.	Office-Wide Innovative Solutions Opening for Health Science Futures (HSF) ARPA-H-SOL-24-104	HSF awardees will develop innovative technologies, tools, and platforms that can be applied to a broad range of diseases. The following interest areas define the ground-breaking research we seek to support: Breakthrough Technologies; Transformative Tools; and Platform Systems. https://sam.gov/opp/9a301dc812ba47268323e3130e381f19/view	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25
82.	Office-Wide Innovative Solutions Opening for Scalable Solutions Office (SSO) ARPA-H-SOL-24-105	ARPA-H SSO seeks solutions to improve the scalability and affordability of health care solutions, bridge gaps in underserved areas, and extend remote access to expertise by developing location-specific interventions, telemedicine solutions, and mobile health clinics. Solutions should focus on rapid innovation and the use of partnerships, as well as flexible distribution networks and streamlined manufacturing processes. SSO interest areas include: Scalable Technologies and Interventions; Collaborative Distribution Networks; and Biomanufacturing Innovations. https://sam.gov/opp/134cdc5d93b34c0ea39498055f315624/view	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25
83.	Office-Wide Innovative Solutions Opening for Proactive Health Office (PHO) ARPA-H-SOL-24-106	The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Interest areas include: Novel prevention, detection and prophylactic treatment methods for disease; Population-level approaches to increase the adoption of prevention and wellness behaviors; and System innovation for the delivery of proactive health outcomes. https://sam.gov/opp/53707a1538994e7d9ed8df8e5ee95ed1/view	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AIR FORCE (3)		
84.	Airman Readiness Medical Research (ARMR) Hybrid BAA FA8650-20-S-6008	The Warfighter Medical Optimization Division intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance. https://www.grants.gov/search-results-detail/327332	Up to \$49 million, per award	White papers accepted on rolling basis until 5/1/25
85.	Research Interests of the Air Force Office of Scientific Research FA9550-23-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. These areas are organized and managed in two scientific Departments: Engineering and Information Science (RTA), Physical and Biological Sciences (RTB), and our international offices (EAORD, SOARD, and AOARD). https://www.grants.gov/search-results-detail/345653	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis
86.	Research Interests of the United States Air Force Academy USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. https://www.grants.gov/search-results-detail/330175	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis
		ARMY (9)		
87.	The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense Broad Other Transaction Authority Announcement (BOTAA) BOTAA-24-01	JPEO-CBRND is interested in efforts directed toward the development of enabling technologies that speed up the advanced development process. Areas of interest include: Software and Artificial Intelligence (AI), wearable sensors, threat detection, biothreat containment and aeromedical evaluation. https://sam.gov/opp/2d04622b25364669857a6a61c576ade9/view	Dependent upon proposal	Preproposals accepted through 2/7/29



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
88.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. https://sam.gov/opp/f2d01f5a6c444e32af543e9519a0805f/view	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
89.	USAMRDC Broad Agency Announcement for Extramural Medical Research HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; and Military Operational Medicine. https://www.grants.gov/search-results-detail/343725	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation
90.	USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development HT9425-23-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries; PFC; human performance optimization; canine medicine/performance; brain health; immune response; automation of systematic reviews and metanalysis; and novel post-traumatic stress, depression, and anxiety treatment. SOF medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/search-results-detail/349586	Dependent upon proposal	Proposals accepted through 7/31/28 Submission of a pre-proposal is required
91.	Army Research Office Laboratory Broad Agency Announcement for Foundational Research W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition; the full list of research topics is available here: https://www.arl.army.mil/opportunities/arl-baa/ https://sam.gov/opp/7560e5d4024b4e94ad3eab6180cfcc36/view	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27
92.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://sam.gov/opp/ee8d9eeec4f94269b6e1ac16b09d9417/view	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
93.	Army Applications Lab BAA for Disruptive Applications W911NF-24-S-0008	AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch. https://sam.gov/opp/3f8ec6d36d584ca28364a2f8a10255b7/view	Dependent upon proposal	Proposals accepted through 4/4/29 Pre-proposal is required
94.	Army Combat Capabilities Development Command Broad Agency Announcement W911QY20R0022	Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest. https://www.grants.gov/search-results-detail/327285	Dependent upon proposal	Proposals accepted on a rolling basis until 2/28/25
95.	BAA for Chemical, Biological, Radiological, Nuclear, and Explosive Defense Efforts W911SR-24-R-DEVB	DEVCOM CBC's mission is to provide innovative chemical, biological, radiological, nuclear and explosive (CBRNE) defense capabilities to enable the Joint Warfighters' dominance on the battlefield and interagency defense of the homeland. Mission areas include: Sensor technologies and biomaterials; Biological point detection; Chemical point detection; Early warning and detection; Collective protection; Respiratory protection; Decontamination; CBRN countermeasures; and Chemical biological advanced materials and manufacturing science. https://sam.gov/opp/6e54cc4efcob4aae97ed39666a15b004/view	Dependent upon proposal and award mechanism	Preproposals accepted through 8/20/29
		BARDA (2)		
96.	BARDA Broad Agency Announcement BAA-23-100-SOL-00004	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antimicrobials; Radiological/Nuclear MCMs; Chemical Threat MCMs; Burn and Blast Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; ImmuneChip+; Flexible and Strategic Therapeutics (FASTx). https://sam.gov/opp/65e6d7784edd4e83840c3794dc8d47/view	Dependent upon proposal	Proposal: 9/25/28
97.	BARDA DRIVe EZ-BAA DRIVeEZBAA22100SOL00003	BARDA is currently accepting submissions through the EZ-BAA for several AOIs: AOI #15: ReDIRECT; AOI #19: Healing Lungs; AOI #22: ReBooT; AOI #28: Influenza Vaccine Innovation. https://sam.gov/opp/8f4d63db541c46ff9e339d8c43doad86/view	Up to \$750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DARPA (2)		
98.	Biological Technologies BAA HR001124S0034	Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. BTO is interested in submissions related to the following topic areas: AI/ML; Human Performance; Materials, Sensors, Processing; Ecosystem and Environmental; Biosecurity and Biosafety; and Biomedical and Biodefense. https://sam.gov/opp/5fff3c4c76c341a4a6b1d2010211c793/view	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 9/10/25
99.	Defense Sciences Office, Office-wide HR001124S0039	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Novel Materials & Structures; Sensing and Measurement; Computation and Processing; Enabling Operations; Collective Intelligence; and Emerging Threats. https://sam.gov/opp/3c1deaa286b74897bed07f3eefb446a0/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 9/26/25
		DEFENSE THREAT REDUCTION AGENCY (4)		
100.	Research and Development Innovations Broad Agency Announcement HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the 2022 DTRA Strategic Plan for RDT&E (plan available at https://www.dtra.mil/): <ul style="list-style-type: none"> • Understand current and emerging WMD situations, threats, and capabilities • Enable effective and integrated WMD deterrence • Control, disable, and defeat current and emerging WMD threats • Protect the force and mitigate crises from WMD • Enable cross-cutting capabilities https://sam.gov/opp/45f3e82bc46c4d3f89560b700d1123cd/view	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27
101.	Biological Threat Reduction with Global Partners Broad Agency Announcement (BAA) HDTRA1-24-S-0002	BTRP supports international health security efforts to address diseases caused by U.S. Biological Select Agents, pathogens of pandemic potential, and emerging infectious diseases. BTRP achieves its mission through collaboration with partner countries and the international community to minimize the threat of deliberate, accidental, and natural infectious disease outbreaks through enhanced detection, diagnosis, and reporting capabilities and biosecurity and biosafety measures. https://www.grants.gov/search-results-detail/353860	Dependent upon proposal and award mechanism	Proposal: 4/28/29
102.	FY25-29 Strategic Trends Research Initiative Broad Agency Announcement HDTRA1-24-S-0003	SI-ST's research explores a range of challenges related to nuclear, chemical, and biological weapons. The three WMD-relevant Research Thrust Areas are: strategic international dialogues, analytical studies, and emerging CWMD researcher projects. An area of general interest is: Future trends related to biological warfare, biodefense, biosecurity, and bio preparedness. https://sam.gov/opp/7a98bf70ac2a49c8b8eod71abbc93750/view	Dependent upon proposal and award mechanism`	White papers accepted on a rolling basis through 8/1/29



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEFENSE THREAT REDUCTION AGENCY		
103.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) HDTRA1-25-S-0001	Fundamental research efforts enable capabilities such as development of improved detection devices for traditional and nontraditional chemical agents; development of diagnostics for existing and emerging infectious disease threats; increasing knowledge and improved capabilities for development of new or improved medical and material countermeasures to CB threats for both pre- and post-exposure scenarios; enhanced personal protection against, modeling of, prevention of, or decontamination of CB threats; and providing effective elimination strategies via non-kinetic approaches for threat agent destruction, neutralization and/or sequestration. https://www.grants.gov/search-results-detail/356612	Up to \$1 million per year, for up to 5 years	White papers accepted through 9/2034
		DEPARTMENT OF ENERGY (1)		
104.	FY 2025 Continuation of Solicitation for the Office of Science Financial Assistance Program DE-FOA-0003432	SC accomplishes its mission and advances national goals by supporting: The frontiers of science—exploring nature’s mysteries from the study of fundamental subatomic particles, atoms, and molecules that are the building blocks of the materials of our universe and everything in it to the DNA, proteins, and cells that are the building blocks of life. Each of the programs in SC supports research probing the most fundamental disciplinary questions. https://www.grants.gov/search-results-detail/356590	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/25
		NATIONAL SCIENCE FOUNDATION (2)		
105.	Small Business Innovation Research Program Phase I (SBIR/STTR Phase I) NSF 24-579	The NSF SBIR and STTR programs focus on transforming scientific discovery into products and services with commercial potential and/or societal benefit. Unlike fundamental or basic research activities that focus on scientific and engineering discovery itself, the NSF SBIR program supports the creation of opportunities to move fundamental science and engineering out of the lab and into the market or other use at scale, or startups and small businesses representing "deep technology ventures." The programs fund research and development, and are designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development. The required Project Pitch allows startups and small businesses to get quick feedback at the start of their application for Phase I funding. View the full list of topics. https://new.nsf.gov/funding/opportunities/nsf-small-business-innovation-research-small-o/nsf24-579/solicitation	Up to \$275,000 for up to 1 year	Project pitches accepted on a rolling basis through 11/5/25.



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NATIONAL SCIENCE FOUNDATION		
106.	NSF Small Business Innovation Research / Small Business Technology Transfer Fast-Track Pilot Programs (SBIR-STTR Fast-Track) NSF 24-582	The NSF SBIR/STTR Fast-Track programs provide non-dilutive, fixed amount cooperative agreements for the development of a broad range of technologies based on discoveries in science and engineering with the potential for societal and economic impacts. https://new.nsf.gov/funding/opportunities/nsf-small-business-innovation-research-small-1/nsf24-582/solicitation	Up to \$1,555,000, for up to 3 years	Project pitches accepted on a rolling basis through 11/5/25
		NAVY (3)		
107.	FY25 Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology N0001425SB001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://www.onr.navy.mil/work-with-us/funding-opportunities/fy25-long-range-broad-agency-announcement-baa-navy-and-marine	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/25
108.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research N00173-24-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. https://sam.gov/opp/c3199ba7fb2f46edb15f99ade96c14a7/view	Dependent upon proposal and award mechanism	White papers accepted through 2/28/25
109.	FY24 Broad Agency Announcement for Innovative Environmental Technologies and Methodologies N3943024S2000	This announcement seeks out technologies and methodologies to reduce environmental impacts from current and past Navy operations, and applies to Navy installations worldwide. NEXWC is interested in environmental technologies and methodologies that are either new, innovative, advance the state-of-the art, or increase knowledge or understanding of a technology or methodology. https://sam.gov/opp/2397c9059c3942cfb618400b2d8637e2/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 4/7/25
		OFFICE OF THE UNDERSECRETARY OF DEFENSE (1)		
110.	OUSD(R&E) Seeks Advanced Manufacturing, Prototypes and Materials (AMPAM) HQ003425BOTA1	OUSD(R&E)'s goal is to foster increased collaboration and partnership between Government and Industry to identify, develop, and mature new or improved manufacturing and repair processes and bridge the gap between discovery and implementation of new capabilities for the warfighter. Examples may include Bio-manufacturing of medical related material and Bio-manufacturing of materials or products in the supply chain. https://sam.gov/opp/64a31b87112843b58dfb13f37bfa3df1/view	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis through 10/2/27



	Title (Agency) and Opportunity #	Description and Link (8)	Funding Level	Deadline
		PATIENT-CENTERED RESEARCH INSTITUTE (8)		
111.	Phased Large Awards for Comparative Effectiveness Research (PLACER) – Cycle 1 2025	<p>This PFA invites applications for high-quality comparative clinical effectiveness research (CER) projects that will address critical decisions faced by patients, caregivers, clinicians, and stakeholders across the health and healthcare community and for which there is insufficient evidence. Applications must address at least one of the National Priorities for Health.</p> <p>https://www.pcori.org/funding-opportunities/announcement/phased-large-awards-comparative-effectiveness-research-pcori-funding-announcement-cycle-1-2025</p>	Up to \$22 million, for up to 6.5 years	Letter of intent: 1/14/25 Proposal: 5/6/25
112.	Broad Pragmatic Studies Funding Announcement -- 2024 Standing PFA -- Cycle 1 2025	<p>This PFA invites applications for high-quality comparative clinical effectiveness research projects. All applications must align the proposed research with at least one of the National Priorities for Health. Applicants have the option to choose up to three of twelve topic themes, based on how their proposed research aligns with the themes. Cycle 3 SAEs include: Social Isolation and Loneliness in Older Adults, Health Communication Strategies for Uptake of COVID-19 Vaccine, and Promoting Sleep Health in Inpatient Settings.</p> <p>https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-pcori-funding-announcement-cycle-1-2025</p>	Up to \$12 million, for up to 5 years Dependent upon award mechanism	Letter of intent: 1/14/25 Proposal: 5/6/25
113.	Advancing the Science of Engagement PCORI Funding Announcement -- Cycle 1 2025	<p>This PFA will fund studies that build an evidence base on engagement in research, including: Measures to capture structure/context, process, and outcomes; Techniques that lead to effective engagement; How these techniques should be modified and resourced for different contexts, settings, and communities to ensure equity; How engagement supports successful research.</p> <p>https://www.pcori.org/funding-opportunities/announcement/advancing-science-engagement-research-pcori-funding-announcement-cycle-1-2025</p>	Up to \$1.5 million, for up to 3 years	Letter of intent: 1/14/25 Proposal: 5/6/25
114.	Improving Methods for Conducting Patient-Centered Comparative Clinical Effectiveness Research -- Cycle 1 2025	<p>For this PFA, PCORI has identified the following areas as programmatic priorities: Methods to Improve the Use of AI and ML in Clinical Research; Methods to Improve Study Design; Methods to Support Data Research Networks; Methods Related to Ethical and Human Subjects Protections Issues in CER.</p> <p>https://www.pcori.org/funding-opportunities/announcement/improving-methods-conducting-patient-centered-comparative-clinical-effectiveness-research-pcori-funding-announcement-cycle-1-2025</p>	Up to \$750,000, for up to 3 years	Letter of intent: 1/14/25 Proposal: 5/6/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED RESEARCH INSTITUTE		
115.	Open Competition PFA: Implementation of Findings from PCORI's Major Research Investments -- Cycle 1 2025	For this PFA, PCORI has identified the following four areas of eligible evidence: Obesity Treatment in Primary Care Settings; Nonsurgical treatment options can improve or eliminate symptoms for women with urinary incontinence (UI); Several kinds of therapy and medicines can reduce or stop symptoms for people with PTSD; The use of narrow-spectrum versus broad-spectrum antibiotics to treat children's acute respiratory tract infections (ARTIs). https://www.pcori.org/funding-opportunities/announcement/open-competition-implementation-findings-pcoris-research-investments-pcori-funding-announcement-cycle-1-2025	Up to \$2.5 million, for up to 3 years	Letter of intent: 1/14/25 Proposal: 5/6/25
116.	Engagement Award: Capacity Building -- Spring 2025 Cycle	The Engagement Award: Capacity Building opportunity funds projects that build communities prepared to participate in PCOR/CER. These awards support organizations with strong ties to patients, caregivers, clinicians, and other stakeholders who have a connection to a research focus area and seek to better equip stakeholders to engage as partners in PCOR/CER. https://www.pcori.org/funding-opportunities/announcement/engagement-award-capacity-building-spring-2025-cycle	Up to \$300,000, for up to 2 years	System opens: 1/16/25 Letter of intent: 4/1/25 Proposal: 7/10/25
117.	Engagement Award: Stakeholder Convening Support -- Spring 2025 Cycle	The Engagement Award: Stakeholder Convening Support funding opportunity provides support to organizations and communities to hold multi-stakeholder convenings, meetings, and conferences that include a combination of patients, caregivers, researchers, clinicians, purchasers, payers, health system leaders, and/or other stakeholders. Convenings should be designed with the active collaboration and partnership of patients, community groups, and/or other stakeholder organizations. https://www.pcori.org/funding-opportunities/announcement/engagement-award-convening-support-spring-2025-cycle	Up to \$125,000, for up to 1 year	System opens: 1/16/25 Letter of intent: 4/1/25 Proposal: 7/10/25
118.	Engagement Award: Dissemination Initiative -- Spring 2025 Cycle	The Engagement Award: Dissemination Initiative funding opportunity aims to support projects that help organizations and communities plan for or actively bring pertinent PCORI-funded research findings to their specific audiences, including relevant patients, clinicians, communities, and others, in ways that will command their attention and interest and encourage use of this information in their healthcare decision making. https://www.pcori.org/funding-opportunities/announcement/engagement-award-dissemination-initiative-spring-2025-cycle	Up to \$300,000, for up to 2 years	System opens: 1/16/25 Letter of intent: 4/1/25 Proposal: 7/10/25





Terms

AoI: Area of Interest
BAA: Broad Agency Announcement
FOA: Funding Opportunity Announcement
IC: NIH Institutes and Centers
NOFO: Notice of Funding Opportunity
NOSI: Notice of Special Interest
PI: Principal Investigator
RFI: Request for Information
RFP: Request for Proposal
SBIR: Small Business Innovation Research
SDOH: Social Determinants of Health
STTR: Small Business Technology Transfer
TRL: Technology Readiness Level

Agencies

ARPA-H: Advanced Research Projects Agency for Health
ASPR: Administration for Strategic Preparedness and Response
BARDA: Biomedical Advanced Research and Development Authority
CDC: Centers for Disease Control and Prevention
CDMRP: Congressionally Directed Medical Research Programs
DARPA: Defense Advanced Research Projects Agency
DHA: Defense Health Agency
DoD: Department of Defense
FDA: U.S. Food and Drug Administration
MTEC: Medical Technology Enterprise Consortium
NIH: National Institutes of Health
NSF: National Science Foundation
PCORI: Patient-Centered Outcomes Research Institute
USAMRDC: U.S. Army Medical Research and Development Command
USAMRIID: U.S. Army Medical Research Institute of Infectious Diseases
USSOCOM: United States Special Operations Command

GBG Acronyms

Updated Monthly

January 8, 2025

<https://www.g2gconsulting.com/gbg-reporting-service/>

NIH Institutes and Centers

CC: NIH Clinical Center
CIT: NIH Center for Information Technology
CSR: NIH Center for Scientific Review
FIC: Fogarty International Center
NCATS: National Center for Advancing Translational Sciences
NCCIH: National Center for Complementary and Integrative Health
NCI: National Cancer Institute
NEI: National Eye Institute
NHGRI: National Human Genome Research Institute
NHLBI: National Heart, Lung, and Blood Institute
NIA: National Institute on Aging
NIAAA: National Institute on Alcohol Abuse and Alcoholism
NIAID: National Institute of Allergy and Infectious Diseases
NIAMS: National Institute of Arthritis & Musculoskeletal & Skin Diseases
NIBIB: National Institute of Biomedical Imaging and Bioengineering
NICHD: Eunice Kennedy Shriver National Institute of Child Health and Human Development
NIDA: National Institute on Drug Abuse
NIDCD: National Institute on Deafness and Other Communication Disorders
NIDCR: National Institute of Dental and Craniofacial Research
NIDDK: National Institute of Diabetes and Digestive and Kidney Diseases
NIHES: National Institute of Environmental Health Sciences
NIGMS: National Institute of General Medical Sciences
NIMH: National Institute of Mental Health
NIMHD: National Institute on Minority Health and Health Disparities
NINDS: National Institute of Neurological Disorders and Stroke
NINR: National Institute of Nursing Research
NLM: National Library of Medicine

